Search results for "polymorphism"

showing 10 items of 1968 documents

Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis.

2008

Abstract The pro-inflammatory cytokine interleukin(IL)-1β is a main component in inflammatory pathways and is overexpressed in the brain of Alzheimer's disease (AD) patients. Several studies report associations between IL-1β polymorphisms and AD, but findings from different studies are controversial. Our aim was to verify the correlation between the single nucleotide polymorphisms (SNPs) of the IL-1β, at sites − 511 and + 3953, and AD by meta-analysis. Computerized bibliographic searches of PUBMED and AlzGene database ( http://www.alzgene.org ) were supplemented with manual searches of reference lists. There is evidence for association between IL-1β + 3953 SNP and AD, with an OR = 1.60 (95%…

OncologyDatabases Factual statistics /&/ numerical datamedicine.medical_specialtyDatabases FactualAlzheimer's disease IL-1β −511 IL-1β +3953 Polymorphism Meta-analysisPopulationInterleukin-1betaSingle-nucleotide polymorphismSubgroup analysisAlzheimer Disease geneticsMeta-Analysis as TopicPolymorphism (computer science)Alzheimer DiseaseInternal medicineGenotypemedicineSNPHumanseducationSettore MED/04 - Patologia Generaleeducation.field_of_studyPolymorphism Geneticbusiness.industryGeneral NeuroscienceComputational Biologymedicine.diseaseMeta-analysisImmunologyNeurology (clinical)Alzheimer's diseasebusinessInterleukin-1beta genetics
researchProduct

Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.

2012

Lifetime exposure to estrogen is a factor that plays an important role in the pathogenesis and progression of breast cancer. Genetic variants in genes of the biosynthesis and metabolism of estrogen have been associated with breast cancer risk. Among them, the CYP19 gene encodes for aromatase, the enzyme that catalyzes the conversion of androgens to estrogens. The rs10046 polymorphism on the CYP19 gene has been related to levels of circulating estradiol and to the estradiol/testosterone ratio. To date, epidemiological studies of rs10046 have been performed in different populations with contradictory results. In the present study, we have conducted a case-control analysis (522 cases and 1221 …

OncologyEpidemiologylcsh:MedicineBreast TumorsAromataselcsh:ScienceAged 80 and overMultidisciplinarybiologyObstetrics and GynecologyMiddle AgedOncologyMeta-analysisMedicineFemaleCancer EpidemiologyResearch ArticleAdultmedicine.medical_specialtyAdolescentmedicine.drug_classBreast NeoplasmsPolymorphism Single NucleotideYoung AdultBreast cancerAromataseInternal medicineGenetic modelBreast CancermedicineGeneticsHumansGenetic Predisposition to DiseaseAlleleBiologyAgedPopulation Biologylcsh:RCase-control studyReproducibility of ResultsCancers and NeoplasmsOdds ratiomedicine.diseaseEndocrinologyEstrogenCase-Control Studiesbiology.proteinGenetic PolymorphismWomen's Healthlcsh:QPopulation GeneticsPLoS ONE
researchProduct

Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia

1999

Germ-line mutations of the BRCA1 gene account for approximately half of the cases of hereditary breast/ovarian cancers. We have screened index patients from 15 breast cancer families and 8 sporadic breast cancer patients from Latvia for mutations in all coding exons of the BRCA1 gene, using combined Heteroduplex Analysis/SSCP followed by direct sequencing of the variants. BRCA1 germ-line mutations proved to be frequent in Latvian breast cancer patients, also in moderate-risk families and sporadic patients. Out of 23 cases a total of 8 patients (35%) exhibited three different mutations (5382insC, C61G, 4153delA). Interestingly, these three recurrent mutations accounted for all mutations in o…

OncologyGeneticsmedicine.medical_specialtyMutationDirect sequencingSingle-strand conformation polymorphismBiologymedicine.diseasemedicine.disease_causeExonBreast cancerInternal medicineGeneticsmedicineGenetics (clinical)Brca1 geneFounder effectHeteroduplexHuman Mutation
researchProduct

CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients

2014

Background Neuroblastoma is a pediatric cancer that exhibits a wide clinical spectrum ranging from spontaneous regression in low-risk patients to fatal disease in high-risk patients. The identification of single nucleotide polymorphisms (SNPs) may help explain the heterogeneity of neuroblastoma and assist in identifying patients at higher risk for poor survival. SNPs in the TP53 pathway are of special importance, as several studies have reported associations between TP53 pathway SNPs and cancer. Of note, less than 2% of neuroblastoma tumors have a TP53 mutation at diagnosis. Patients and Methods We selected 21 of the most frequently studied SNPs in the TP53 pathway and evaluated their assoc…

OncologyGenotyping TechniquesMedizinlcsh:MedicineGenome-wide association studyPROGRESSIONSUSCEPTIBILITYBioinformaticsNeuroblastomaCHEMOSENSITIVITYMedicine and Health SciencesMissense mutationlcsh:ScienceOncogene ProteinsCaspase 8N-Myc Proto-Oncogene ProteinMultidisciplinaryCELL-LINENuclear ProteinsCANCERAPOPTOSISGENOTYPEGene Expression Regulation NeoplasticResearch Articlemedicine.medical_specialtySingle-nucleotide polymorphismBiologyN-Myc Proto-Oncogene ProteinPolymorphism Single NucleotideDisease-Free SurvivalMDM2 SNP309Molecular GeneticsNeuroblastomaInternal medicineCASPASE-8medicineGeneticsCancer GeneticsSNPHumansneoplasmsNeoplasm StagingClinical GeneticsP53lcsh:RGene AmplificationCancerInfantBiology and Life Sciencesmedicine.diseasePediatric cancerGeriatricsGenetics of Diseaselcsh:Q
researchProduct

The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives

2019

In recent decades, non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in the Western world, and the occurrence of its complications, such as hepatocellular carcinoma (HCC), has rapidly increased. Obesity and diabetes are considered not only the main triggers for the development of the disease, but also two independent risk factors for HCC. Single nucleotide polymorphisms (such as PNPLA3, TM6SF2 and MBOAT7) are related to the susceptibility to the development of HCC and its progression. Therefore, an appropriate follow-up of these patients is needed for the early diagnosis and treatment of HCC. To date, international guidelines recommend the use of ultrasonogr…

OncologyHepatocellular carcinomaDiseaseReviewlcsh:ChemistryLiver disease0302 clinical medicineDisease ScreeningRisk FactorsMass ScreeningHCClcsh:QH301-705.5SpectroscopyFatty liverLiver NeoplasmsGeneral MedicineComputer Science Applications030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyMiRNAmedicine.medical_specialtyMicro RNACarcinoma HepatocellularSingle-nucleotide polymorphismCatalysisTM6SF2Inorganic ChemistryDiabetes Complications03 medical and health sciencesDiabetes mellitusInternal medicineNAFLDmedicineAnimalsHumansObesityPhysical and Theoretical ChemistryMolecular BiologyPNPLA3Long non-conding RNAbusiness.industryOrganic Chemistrymedicine.diseasedigestive system diseasesLncRNAlcsh:Biology (General)lcsh:QD1-999businessTM6SF2Non-alcoholic fatty liver disease
researchProduct

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

2018

Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma (HCC) since 2007 and numerous studies have investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysi…

OncologyHepatocellular carcinomalaw.inventionLeukocyte Count0302 clinical medicineRandomized controlled trialNeutrophil-tolymphocyte ratiolawMedicineNeutrophil-to-lymphocyte ratioLiver NeoplasmsGastroenterologyMicroRNAGeneral MedicineSorafenibPrognosisTreatment OutcomeLiver030220 oncology & carcinogenesisHepatocellular carcinomaBiomarker (medicine)030211 gastroenterology & hepatologyAdverse events; Angiopoietin; Biomarker; Hepatocellular carcinoma; MicroRNA; Neutrophil-tolymphocyte ratio; Polymorphisms; Sorafenib; Vascular endothelial growth factor; Gastroenterologymedicine.drugAdverse eventSorafenibmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsSingle-nucleotide polymorphismAngiopoietin03 medical and health sciencesInternal medicineBiomarkers TumorHumansNeoplasm InvasivenessPolymorphismNeutrophil to lymphocyte ratioAdverse effectbusiness.industryBiomarkermedicine.diseasedigestive system diseasesClinical Trials Phase III as TopicDrug Resistance NeoplasmAdverse eventsEtiologyVascular endothelial growth factorbusinessPolymorphisms
researchProduct

Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations

2013

<b><i>Objectives:</i></b> The rapid fatality of pancreatic cancer is, in large part, the result of diagnosis at an advanced stage in the majority of patients. Identification of individuals at risk of developing pancreatic adenocarcinoma would be useful to improve the prognosis of this disease. There is presently no biological or genetic indicator allowing the detection of patients at risk. Our main goal was to identify copy number variants (CNVs) common to all patients with sporadic pancreatic cancer. <b><i>Methods:</i></b> We analyzed gene CNVs in leukocyte DNA from 31 patients with sporadic pancreatic adenocarcinoma and from 93 matched contr…

OncologyMaleCancer Researchmedicine.medical_specialtySettore MED/06 - Oncologia MedicaGene DosageCancer-associated genesBiologyAdenocarcinomaGene dosagePolymorphism Single NucleotideSensitivity and SpecificityGermlineGermline mutationGermline alterationsPolymorphism (computer science)Internal medicinePancreatic cancermedicinepancreatic adenocarcinomaHumansGenetic Predisposition to DiseaseCopy number variationsCopy-number variationGerm-Line MutationGermline alterationAgedCancer-associated geneCopy number variations; Cancer-associated genes; Germline alterations; Sporadic pancreatic cancerCopy number variationCase-control studyGeneral MedicineDNA NeoplasmMiddle Agedmedicine.diseasePancreatic NeoplasmsSporadic pancreatic cancerOncologyTissue Array AnalysisCase-Control StudiesAdenocarcinomaFemale
researchProduct

The association between Mediterranean Diet Score and glucokinase regulatory protein gene variation on the markers of cardiometabolic risk: an analysi…

2014

Consumption of a Mediterranean diet (MD) and genetic variation in the glucokinase regulatory protein (GCKR) gene have been reported to be associated with TAG and glucose metabolism. It is uncertain whether there is any interaction between these factors. Therefore, the aims of the present study were to test the association of adherence to a MD and rs780094 (G>A) SNP in theGCKRgene with the markers of cardiometabolic risk, and to investigate the interaction between genetic variation and MD adherence. We studied 20 986 individuals from the European Prospective Investigation into Cancer (EPIC)-Norfolk study. The relative Mediterranean Diet Score (rMED: range 0–18) was used to assess MD adher…

OncologyMaleMediterranean dietMedicine (miscellaneous)030204 cardiovascular system & hematologyDiet MediterraneanCohort Studies0302 clinical medicineGenotype030212 general & internal medicineProspective StudiesGene–environment interactionProspective cohort studyNutrition and DieteticsGlucokinase regulatory proteinConfoundingDietary Surveys and Nutritional EpidemiologyMiddle AgedFull PapersLipids3. Good healthEnglandCardiovascular DiseasesFemaleAdultRiskmedicine.medical_specialtyBiologyPolymorphism Single Nucleotide03 medical and health sciencesInternal medicineMediterranean dietGenetic variationmedicineSNPHumansGenetic Association StudiesAdaptor Proteins Signal TransducingAgedGlycated HemoglobinCardiometabolic riskEndocrinologyCross-Sectional StudiesApolipoproteinsDiabetes Mellitus Type 2biology.proteinPatient ComplianceGene-Environment InteractionGlucokinase regulatory proteinBiomarkersThe British journal of nutrition
researchProduct

Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.

2019

International audience; Epidemiologic studies show an increased risk of non-Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen-stimulation in one disease leads to another. Here we assess shared genetic risk in genome-wide-association-studies (GWAS). Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (a) description of regional g…

OncologyMaleMultifactorial InheritanceLymphomaEpidemiologyChronic lymphocytic leukemiaFollicular lymphomaGenome-wide association studyDiseaseNeurodegenerativemeta-analysiimmune system diseasesHLA AntigensRisk Factorshemic and lymphatic diseases2.1 Biological and endogenous factorsHLA AntigenAetiologyGenetics (clinical)CancerAllele0303 health sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyLymphoma Non-Hodgkinnon-Hodgkin lymphoma030305 genetics & hereditySingle NucleotideHematologyMiddle Aged3. Good healthnon-Hodgkin lymphoma.Public Health and Health ServicesFemaleHumanmedicine.medical_specialtyautoimmune disease; genome-wide association study; meta-analysis; non-Hodgkin lymphoma; Alleles; Autoimmune Diseases; Female; HLA Antigens; Humans; Lymphoma Non-Hodgkin; Male; Middle Aged; Multifactorial Inheritance; Polymorphism Single Nucleotide; Risk Factors; Genetic Predisposition to DiseaseNon-Hodgkinautoimmune diseasePolymorphism Single NucleotideArticleAutoimmune Diseases03 medical and health sciencesRare DiseasesInternal medicineGenetic variationmedicineGeneticsHumansGenetic Predisposition to DiseasePolymorphismAlleles030304 developmental biologyAutoimmune diseasegenome-wide association studybusiness.industryMultiple sclerosisRisk FactorArthritisInflammatory and immune systemHuman Genomemedicine.diseaseLymphomaBrain Disordersmeta-analysisbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study

2015

OBJECTIVE: We aimed to better clarify the role of germline variants of the FCG2 receptor, FCGR2A-H131R and FCGR3A-V158F, on the therapeutic efficacy of cetuximab in metastatic colorectal cancer (mCRC). A large cohort with sufficient statistical power was assembled.DESIGN: To show a HR advantage of 0.6 in progression-free survival (PFS) for FCGR2A-HH versus the rest and FCGR3A-VV versus the rest, with an 80% power, 80 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) wild-type (KRAS-WT) and 52 KRAS-WT patients are required, respectively. This leads to a total sample size of 952 and 619 patients, respectively. Samples were collected from 1123 mCRC patients from 15 European centres treated wit…

OncologyMaleReceptors IgG/geneticsGenotyping TechniquesColorectal cancermedicine.medical_treatmentCetuximabmedicine.disease_causeGenetic PolymorphismsErbB Receptors/antagonists & inhibitorsNeoplasm MetastasisAntibody Targeted TherapyImmune ResponseAged 80 and overbiologyCetuximabGastroenterologyColorectal Neoplasms/drug therapyMiddle AgedErbB ReceptorsSurvival RateAntibodies Monoclonal Humanized/therapeutic useFemaleKRASAntibodyColorectal Neoplasmsmedicine.drugAdultmedicine.medical_specialtyAntineoplastic AgentsAntibodies Monoclonal HumanizedDisease-Free SurvivalYoung AdultRefractoryInternal medicinemedicineHumansneoplasmsGerm-Line MutationAgedColorectal CancerChemotherapyPolymorphism Geneticbusiness.industryReceptors IgGAntineoplastic Agents/therapeutic usemedicine.diseasedigestive system diseasesOxaliplatinIrinotecanImmunologybiology.proteinbusinessGenotyping Techniques/standards
researchProduct